BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX Venture Company to Be Recognized as a Top Performer for the...
February 13 2014 - 8:00AM
Marketwired
BioSyent Named to the 2014 TSX Venture Top 50(R) Ranking-Only TSX
Venture Company to Be Recognized as a Top Performer for the Past 3
Consecutive Years
TORONTO, ONTARIO--(Marketwired - Feb 13, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) announced today that it has again
been named as one of the TSX Venture Top 50 companies.
The 2014 TSX Venture 50 is an annual ranking of strong
performing companies listed on the TSX Venture Exchange. The TSX
Venture 50 includes the top 10 companies in five major industry
sectors that have been identified as leaders in Canada's public
venture market. BioSyent is ranked on the list of ten leading
Technology and Life Sciences companies for the year. Companies are
selected based on four equally weighted criteria - return on
investment, trading activity, market capitalization growth, and
analyst coverage. The results were obtained from data to December
31, 2013.
BioSyent is the only TSX Venture Company ranked as a top
performer in each of 2012, 2013, and 2014.
"With more than 2,100 companies listed on the TSX Venture
Exchange, it is a testament to the performance of our team to have
BioSyent named for three consecutive years as one of the TSX
Venture Top 50 companies," said René Goehrum, President and CEO of
BioSyent Inc. "Our business has progressed dramatically since we
were named to the 2012 TSX Venture 50. Being named again to the TSX
Venture 50 is recognition by investors that we have an effective
strategy and that we have been consistently effective in executing
that strategy."
For a direct market quote (15 minute delay) for the TSX Venture
Exchange and other company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the company had 13,626,195
shares issued and outstanding.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture Exchange assumes no responsibility for the
accuracy of this release and neither approves nor disapproves of
the same.
BioSyent Inc.Mr. René C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Aug 2023 to Aug 2024